Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Kostos, Louise Kathleen
Lai, William Yu Ching
Lambroglou, Peter
Medhurst, Elizabeth
Buteau, James Patrick
Sandhu, Shahneen
Tran, Ben
Spain, Lavinia Anne
Conduit, Ciara
Wallace, Roslyn
Alipour, Ramin
Akhurst, Timothy J.
Kong, Grace
Cardin, Anthony
Saghebi, Javad
Kumar, Aravind Ravi
Hofman, Michael S.
Azad, Arun
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Mol Imaging & Therapeut Nucl Med, Canc Imaging, Prostate Canc Theranost & Imaging Ctr Excellence, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页数：1
相关论文
共 50 条
  • [31] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [32] High Activity 177Lu-PSMA Therapy Of Metastatic Castration-resistant Prostate Cancer
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Groener, D.
    Davis, K. H.
    Wichert, J.
    Stefanova, M.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S647 - S648
  • [33] Effectiveness of 177Lu PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Gunalp, Bengul
    Emer, Mustafa
    Ozaydin, Sukru
    Alagoz, Engin
    Ince, Semra
    Ayan, Asli
    Alkan, Sumeyye
    Mahmudov, Sarkhan
    Okuyucu, Kursat
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [34] Cancer-control outcomes with [177Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients
    Wenzel, Mike
    Siech, Carolin
    Garcia, Cristina Cano
    Humke, Clara
    Groener, Daniel
    Kriegmair, Maximilian
    Graefen, Markus
    Maurer, Tobias
    Salomon, Georg
    Banek, Severine
    Chun, Felix K. H.
    Mandel, Philipp
    THERANOSTICS, 2025, 15 (07): : 2672 - 2679
  • [35] Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
    Abdlkadir, Ahmed Saad
    Abufara, Alaa
    Al-Ibraheem, Akram
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 58 (06) : 381 - 382
  • [36] COST-EFFECTIVENESS OF [177LU]LU-PSMA-617 IN PROGRESSIVE PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Brockbank, J.
    Hancock, H.
    Khare, A.
    Joshi, P.
    Risson, V
    VALUE IN HEALTH, 2024, 27 (12) : S121 - S121
  • [37] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [38] Systemic radioligand therapy with 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer
    Eiber, Matthias
    Heck, Matthias
    Tauber, Robert
    Rauscher, Isabel
    D'Alessandria, Calogero
    Maurer, Tobias
    Retz, Margitta
    Wester, Hans
    Schwaiger, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [39] 177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation
    Assadi, Majid
    Pirayesh, Elahe
    Rekabpour, Seyed Javad
    Zohrabi, Farshad
    Jafari, Esmail
    Nabipour, Iraj
    Esmaili, Abdolhamid
    Amini, Abdullatif
    Ahmadzadehfar, Hojjat
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (12) : 978 - 980
  • [40] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
    Brnjic, Antonio
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
12345